Search

Displaying results 8821 - 8830 of 9313 in total
  1. Drug

    BBM-H901

    go.drugbank.com/drugs/DB17704
    Investigational

    It is being investigated for the treatment of hemophilia B.[A259048]

  2. Drug

    FB-101

    go.drugbank.com/drugs/DB17956
    Investigational

    Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]

  3. Drug

    ZR202-CoV

    go.drugbank.com/drugs/DB27995
    Investigational

    ZR202-CoV is under investigation in clinical trial NCT05490108 (Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.).

  4. Drug

    Mezigdomide

    go.drugbank.com/drugs/DB17584
    Investigational

    Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants

  5. Drug

    SIG-205

    go.drugbank.com/drugs/DB18548
    Experimental

    SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer

  6. Drug

    SM-1997

    go.drugbank.com/drugs/DB18670
    Experimental

    [A261816] It is under investigation for the treatment of cutaneous sulfur mustard-induced injury.

  7. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.

  8. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  9. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  10. Drug

    OC-1012

    go.drugbank.com/drugs/DB05834
    Experimental

    OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.